Antimicrobials Market Assessment, By Grade [Food Grade, Pharma Grade, Industrial Grade], By Type [Organics, Inorganics], By Applications [Antiviral Protection, Food Packaging, Bacterial Growth Inhibition, Others], By End-user [Homecare Essentials, Agricul

Antimicrobials Market Assessment, By Grade [Food Grade, Pharma Grade, Industrial Grade], By Type [Organics, Inorganics], By Applications [Antiviral Protection, Food Packaging, Bacterial Growth Inhibition, Others], By End-user [Homecare Essentials, Agriculture, Cleaners & Detergents, Paper & Pulp, Inks & Adhesives, Pharmaceuticals, Personal Care, Others], By Region, Opportunities and Forecast, 2016-2030F

Global antimicrobials market size was valued at USD 41.82 billion in 2022, expected to reach USD 60.4 billion in 2030, with a CAGR of 4.7% for the forecast period between 2023 and 2030. The discovery of antimicrobials has benefited various sectors progressively with the adopted innovations. The incorporated antimicrobials deliver specific characteristics based on the group they belong to. Specific mechanisms, such as inhibiting protein, cell wall, and nuclei acid synthesis, depolarize the cell membrane and inhibit metabolic pathways in bacteria. Antimicrobial peptides have the potential to impart either antimicrobial or anticancer activities that subsequently disrupt microbial cell membranes by making proper interaction with negatively charged phospholipids. Antimicrobials have extensive involvement in the agri-food sector, which is responsible for imprudent use, and their prominent contribution to resistance can diminish the concerns for health emergencies.

Extensive Application in Daily Essentials Augments Market Growth

Several prominent factors of antimicrobial compounds are responsible for their numerous applications in balancing hygienic-critical environments. Incorporating antimicrobial compounds assists in enhancing the cleanliness and freshness of everyday products by restricting the proliferation of unpleasant mold and mildew. Its essential characteristic is preserving plastic products by inhibiting physical degradation from fungi and bacteria. By minimizing stain and odor-causing bacteria, antimicrobial compounds remain potentially active in imparting laundering properties in fabric care products.

The global home care product market has grown significantly from USD 1,095.63 billion in 2022 to USD 1,155.36 billion in 2023, recognized as a phenomenal rising sector. The frequent investment in innovations to develop sustainable and effective home care products has created impeccable opportunities for antimicrobial compounds. Also, with the huge application of antimicrobials in the construction industry, it has market opportunities to grow exponentially with the rise in real estate.

Regulations Adoption with Antimicrobials Implementation

The numerous benefits of antimicrobial agents can be recognized across various sectors, including health treatments. Despite several advantages, inappropriate usage of antimicrobial agents within healthcare facilities can decisively lead to the acquisition of nosocomial infections, drug toxicity, unwanted resistance build-up, etc. The World Health Organization (WHO) has framed effective regulations on different quantities and combinations for using antimicrobial agents in pharmaceuticals. Fixed doses of antimicrobial combinations can be banned if not approved by national or international guidelines. Stringent legislation has been implemented functionally, regulating the antimicrobials prescribed by qualified healthcare professionals.

Several antimicrobial awareness campaigns, such as World Antibiotic Awareness Week held in November each year by the World Health Organization (WHO) and similar relevant campaigns, are frequently organized to address the benefits of antimicrobials and their consumption in the prescribed form.

Scientifically validated clinical studies have been provided with specific regulations to justify the choice and level of antimicrobial agents to be incorporated in health-related applications. Between November 2021 and February 2022, the regulatory entities and experts from international organizations conducted semi-structured interviews with scientists’ regulators for India, Brazil, and South Africa to achieve and improve global and national perspectives on regulatory hurdles and evaluate innovation potential.

Antimicrobials Peptides Incorporated as Anticancer Agents Revolutionizing Healthcare Sector

Structurally described as small cationic or amphipathic molecules, antimicrobial peptides (AMPs) deliver an imperative fundamental defense against bacteria, viruses, and fungi. Several AMPs can target human cancer cells, specifically using their ability to bind the phospholipid phosphatidylserines (PS) that usually appear on the outer leaflet of plasma membranes. Recognized as a significant novel anticancer treatment, AMPs deliver a potential source of effective therapeutic agents and a primary defense against a broad spectrum of pathogens and harmful viruses.

According to the National Center for Health Statistics, the United States diagnosed approximately 1,918,030 cancer cases in 2022, where cancer rate in men was higher with 983,160 cases. Data published by Iqvia reported that the investment in 2022 on global cancer medicines was USD 196 billion, estimated to rise exponentially. The enormous potential for drug innovation in cancer treatment has incredibly generated huge opportunities for antimicrobial peptides globally.

Impact of COVID-19

The outbreak of COVID-19 had an unprecedented impact where the whole of mankind was vulnerable to the infectious disease. Due to the unavailability of significant antibiotics, antimicrobial resistance has successively threatened the entire healthcare system in treating untreatable bacterial infections. Some conventional practices, such as empirical antimicrobial prescription and excessive consumption of antimicrobial hygiene products, negatively impacted the prevalence of antimicrobial resistance. The pandemic significantly accentuated a bridge in sustainable funding across R&Ds of antimicrobial medicines and vaccine innovations. To address such challenges WHO and its partner Drugs for Neglected Diseases initiative (DNDi) progressively built the Global Antibiotic R&D Partnership (GARDP) to develop innovative and novel treatments. During the COVID-19 pandemic, the global market for antimicrobials was growing effectively which encouraged more companies to tackle the conflict of antimicrobial resistance.

Impact of Russia-Ukraine War

The invasion of Russia on Ukraine has led to economic as well as physical devastation that has impacted various sectors leading to instability in sequential investment. In March 2019, the Government of Ukraine has approved the National Action Plan to combat antimicrobial resistance protecting unjustified usage of antimicrobial compounds in applications like livestock, poultry, medicine, crop development, etc. The aggression of Russia has severely impacted Ukraine’s healthcare system leading to increase of numerous bacterial infections among the injured soldiers. The medical aid from Western countries has stabilized the prevailing condition to a certain extent where such countries are regularly putting efforts to combat the war impact on the livelihood of Ukraine.

Key Players Landscape and Outlook

To deal with the antimicrobial resistance (AMR) that poses a serious threat to the healthcare systems in an unprecedented way, data reported that, due to hospital infections, an annual financial loss of around USD 13.5 billion occurred in the United States and the European Union. Bioversys is progressively working on innovations to fight antimicrobial resistance. It has prominently developed a diverse antimicrobial agent pipeline that specifically focuses on pathogens targeting gram-positive, gram-negative, and tuberculosis bacteria. Bioversys, on January 2023, has significantly extended the series C round to reach an investment of USD 35.07 million for AMR action, making its first European-based investment.